Literature DB >> 12740266

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Arnold L Smith1, Stanley B Fiel, Nicole Mayer-Hamblett, Bonnie Ramsey, Jane L Burns.   

Abstract

STUDY
OBJECTIVE: To determine the relationship between the antibiotic susceptibility of Pseudomonas aeruginosa isolated from the sputum of patients with cystic fibrosis (CF) and the patient's response to parenteral antibiotic administration, we performed a retrospective analysis using data from patients in the placebo arm of a phase 3 trial of tobramycin solution for inhalation. All patients were chronically infected with P aeruginosa. Seventy-seven of the 262 patients receiving placebo experienced a pulmonary exacerbation during the trial for which they received therapy with IV tobramycin and ceftazidime. The susceptibility of the P aeruginosa isolates to ceftazidime and tobramycin was determined at trial enrollment by broth microdilution.
DESIGN: The clinical response to combination antibiotic therapy was assessed by analyzing differences in spirometry before and after antibiotic administration. The FEV(1) percent predicted at the first visit after the conclusion of antibiotic administration was compared to the FEV(1) percent predicted prior to antibiotic therapy. The results were analyzed both descriptively and by regression analyses.
RESULTS: The conditions of 54 patients improved, and those of 9 patients worsened, and in 14 patients there was no change in FEV(1) with antibiotic administration. No correlation was observed between the susceptibility of P aeruginosa to tobramycin or ceftazidime and clinical response. Only the three following variables were observed to significantly correlate with FEV(1) after antibiotic treatment on regression analysis: FEV(1) prior to treatment (p < 0.0001); number of days elapsed between the previous FEV(1) measurement and the initiation of IV antibiotic therapy (p < 0.002); and the number of days elapsed between the determination of the minimum inhibitory concentration and the initiation of IV therapy (p < 0.03). No significant trends were observed between the antibiotic susceptibility of P aeruginosa isolates and treatment outcomes.
CONCLUSION: While lack of statistical significance for a trend between bacterial susceptibilities and the response to parenteral antibiotic administration does not mean that no such trend exists, the precision of the confidence intervals allows us to conclude that even if isolate antibiotic susceptibilities affect outcome, the impact would be small and not clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740266     DOI: 10.1378/chest.123.5.1495

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  101 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

Review 4.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 5.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

6.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

Review 7.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

Review 8.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

Review 9.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

10.  Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.

Authors:  Benjamin J Staudinger; Jocelyn Fraga Muller; Skarphéðinn Halldórsson; Blaise Boles; Angus Angermeyer; Dao Nguyen; Henry Rosen; Olafur Baldursson; Magnús Gottfreðsson; Guðmundur Hrafn Guðmundsson; Pradeep K Singh
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.